Pembrolizumab 25 MG/ML [Keytruda]

DRUG4 trials

Sponsors

ARCAGY/ GINECO GROUP, Imperial College London, Maria Sklodowska-Curie National Research Institute of Oncology

Conditions

Adrenocortical CarcinomaLung Cancer, Nonsmall CellPlatinum-sensitive Ovarian CancerRelapsed Ovarian CancerSmall Cell Ovarian Carcinoma

Phase 2

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

RecruitingNCT04602377

ARCAGY/ GINECO GROUPSmall Cell Ovarian Carcinoma

Start: 2021-08-04End: 2030-02-28Target: 27Updated: 2025-11-28

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruitingNCT04713514

ARCAGY/ GINECO GROUPPlatinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer

Start: 2021-08-05End: 2025-12-31Target: 180Updated: 2024-12-02

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

RecruitingNCT05563467

Maria Sklodowska-Curie National Research Institute of OncologyAdrenocortical Carcinoma

Start: 2023-01-31End: 2027-05-31Target: 24Updated: 2025-04-02

Phase 3

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

RecruitingNCT05085028

Imperial College LondonLung Cancer, Nonsmall Cell

Start: 2022-06-23End: 2027-05-31Target: 1750Updated: 2024-03-07

Related Papers

TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer

Future Oncology2024-08-19

TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.

Journal of Clinical Oncology2023-06-013 citations

REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.

Journal of Clinical Oncology2023-06-01

REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment.

2023-05-0111 citations

TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab versus best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.

Journal of Clinical Oncology2022-06-012 citations